Arcturus Therapeutics Holdings Inc (ARCT)

$20.79

-0.36

(-1.7%)▲

Live

Performance

  • $20.44
    $21.20
    $20.79
    downward going graph

    1.68%

    Downside

    Day's Volatility :3.58%

    Upside

    1.93%

    downward going graph
  • $17.52
    $45.00
    $20.79
    downward going graph

    15.73%

    Downside

    52 Weeks Volatility :61.07%

    Upside

    53.8%

    downward going graph

Returns

PeriodArcturus Therapeutics Holdings IncSector (Health Care)Index (Russel 2000)
3 Months
-11.43%
3.6%
0.0%
6 Months
-21.84%
10.2%
0.0%
1 Year
9.42%
19.6%
0.0%
3 Years
-52.55%
16.8%
-23.0%

Highlights

Market Capitalization
571.9M
Book Value
$9.56
Earnings Per Share (EPS)
-2.69
Wall Street Target Price
69.11
Profit Margin
-43.92%
Operating Margin TTM
-42.37%
Return On Assets TTM
-13.6%
Return On Equity TTM
-26.47%
Revenue TTM
163.9M
Revenue Per Share TTM
6.11
Quarterly Revenue Growth YOY
374.0%
Gross Profit TTM
62.9M
EBITDA
-85.7M
Diluted Eps TTM
-2.69
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.26
EPS Estimate Next Year
-2.16
EPS Estimate Current Quarter
-1.6
EPS Estimate Next Quarter
-0.72

Analyst Recommendation

Buy
    87%Buy
    6%Hold
    6%Sell
Based on 16 Wall street analysts offering stock ratings for Arcturus Therapeutics Holdings Inc(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
14
14
Hold
1
1
1
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 232.42%

Current $20.79
Target $69.11

Company Financials

FY18Y/Y Change
Revenue
15.8M
↑ 21.2%
Net Income
-21.8M
↑ 99.83%
Net Profit Margin
-138.29%
↓ 54.42%
FY19Y/Y Change
Revenue
20.8M
↑ 31.97%
Net Income
-25.7M
↑ 18.07%
Net Profit Margin
-123.72%
↑ 14.57%
FY20Y/Y Change
Revenue
9.5M
↓ 54.12%
Net Income
-71.4M
↑ 177.45%
Net Profit Margin
-748.13%
↓ 624.41%
FY21Y/Y Change
Revenue
12.4M
↑ 29.56%
Net Income
-206.9M
↑ 189.87%
Net Profit Margin
-1.7K%
↓ 925.65%
FY22Y/Y Change
Revenue
205.8M
↑ 1564.82%
Net Income
9.3M
↓ 104.52%
Net Profit Margin
4.54%
↑ 1678.32%
FY23Y/Y Change
Revenue
157.7M
↓ 23.33%
Net Income
-29.7M
↓ 417.95%
Net Profit Margin
-18.84%
↓ 23.38%
Q1 FY23Q/Q Change
Revenue
79.7M
↓ 50.18%
Net Income
50.8M
↓ 56.75%
Net Profit Margin
63.66%
↓ 9.66%
Q2 FY23Q/Q Change
Revenue
9.6M
↓ 88.0%
Net Income
-52.6M
↓ 203.54%
Net Profit Margin
-549.4%
↓ 613.06%
Q3 FY23Q/Q Change
Revenue
43.4M
↑ 353.49%
Net Income
-16.2M
↓ 69.13%
Net Profit Margin
-37.4%
↑ 512.0%
Q4 FY23Q/Q Change
Revenue
28.2M
↓ 34.96%
Net Income
-8.6M
↓ 47.15%
Net Profit Margin
-30.39%
↑ 7.01%
Q1 FY24Q/Q Change
Revenue
32.6M
↑ 15.55%
Net Income
-26.8M
↑ 212.81%
Net Profit Margin
-82.27%
↓ 51.88%
Q2 FY24Q/Q Change
Revenue
46.0M
↑ 41.04%
Net Income
-17.2M
↓ 35.8%
Net Profit Margin
-37.45%
↑ 44.82%
FY18Y/Y Change
Total Assets
44.2M
↓ 15.04%
Total Liabilities
30.6M
↑ 67.61%
FY19Y/Y Change
Total Assets
82.1M
↑ 85.85%
Total Liabilities
56.4M
↑ 84.42%
FY20Y/Y Change
Total Assets
476.5M
↑ 480.03%
Total Liabilities
79.9M
↑ 41.8%
FY21Y/Y Change
Total Assets
392.8M
↓ 17.56%
Total Liabilities
164.6M
↑ 106.0%
FY22Y/Y Change
Total Assets
450.4M
↑ 14.66%
Total Liabilities
180.1M
↑ 9.4%
FY23Y/Y Change
Total Assets
429.4M
↓ 4.66%
Total Liabilities
150.9M
↓ 16.21%
Q1 FY23Q/Q Change
Total Assets
470.9M
↑ 4.55%
Total Liabilities
141.6M
↓ 21.36%
Q2 FY23Q/Q Change
Total Assets
430.6M
↓ 8.54%
Total Liabilities
145.5M
↑ 2.72%
Q3 FY23Q/Q Change
Total Assets
457.7M
↑ 6.27%
Total Liabilities
177.6M
↑ 22.08%
Q4 FY23Q/Q Change
Total Assets
429.4M
↓ 6.17%
Total Liabilities
150.9M
↓ 15.03%
Q1 FY24Q/Q Change
Total Assets
418.8M
↓ 2.46%
Total Liabilities
154.9M
↑ 2.64%
Q2 FY24Q/Q Change
Total Assets
388.6M
↓ 7.22%
Total Liabilities
130.0M
↓ 16.05%
FY18Y/Y Change
Operating Cash Flow
-20.8M
↑ 4413.04%
Investing Cash Flow
22.1M
↑ 113.75%
Financing Cash Flow
10.2M
↑ 45.81%
FY19Y/Y Change
Operating Cash Flow
-6.4M
↓ 68.95%
Investing Cash Flow
-818.0K
↓ 103.7%
Financing Cash Flow
41.9M
↑ 310.69%
FY20Y/Y Change
Operating Cash Flow
-42.9M
↑ 565.03%
Investing Cash Flow
-1.7M
↑ 112.96%
Financing Cash Flow
436.1M
↑ 940.74%
FY21Y/Y Change
Operating Cash Flow
-135.0M
↑ 215.07%
Investing Cash Flow
-3.4M
↑ 95.52%
Financing Cash Flow
48.0M
↓ 88.99%
FY22Y/Y Change
Operating Cash Flow
32.0M
↓ 123.69%
Investing Cash Flow
-7.7M
↑ 126.83%
Financing Cash Flow
-2.9M
↓ 105.95%
Q1 FY23Q/Q Change
Operating Cash Flow
-35.9M
↓ 122.38%
Investing Cash Flow
-691.0K
↑ 95.2%
Financing Cash Flow
-27.4M
↑ 1125.99%
Q2 FY23Q/Q Change
Operating Cash Flow
50.8M
↓ 241.64%
Investing Cash Flow
-354.0K
↓ 48.77%
Financing Cash Flow
94.0K
↓ 100.34%

Technicals Summary

Sell

Neutral

Buy

Arcturus Therapeutics Holdings Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Arcturus Therapeutics Holdings Inc
Arcturus Therapeutics Holdings Inc
0.0%
-21.84%
9.42%
-52.55%
113.64%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Arcturus Therapeutics Holdings Inc
Arcturus Therapeutics Holdings Inc
10.3
NA
NA
-3.26
-0.26
-0.14
NA
9.56
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Arcturus Therapeutics Holdings Inc
Arcturus Therapeutics Holdings Inc
Buy
$571.9M
113.64%
10.3
-43.92%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on Arcturus Therapeutics Holdings Inc

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 28.21M → 45.97M (in $), with an average increase of 21.3% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -26.81M → -17.21M (in $), with an average increase of 55.8% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 78.1%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 97.3%

Institutional Holdings

  • Federated Hermes Inc

    17.36%

  • BlackRock Inc

    9.80%

  • ARK Investment Management LLC

    7.27%

  • Nikko Asset Management Americas Inc

    5.78%

  • Sumitomo Mitsui Trust Group Inc

    5.78%

  • State Street Corp

    5.64%

Company Information

founded in 2013 and based in san diego, calif., arcturus therapeutics is poised to become an industry leader in the application of rnai technologies for the treatment of disease and improved quality of life. the company’s aim is to develop breakthrough technology and novel therapeutics for rare diseases for which there is no adequate treatment. backed by a management team with extensive experience in the discovery and development of therapeutic modalities, arcturus is on the forefront of research and development of nanoparticle sirna drug delivery systems.

Organization
Arcturus Therapeutics Holdings Inc
Employees
180
CEO
Mr. Joseph E. Payne M.Sc.
Industry
Health Technology

Discover More

FAQs